Aspergillus species intrinsically resistant to antifungal agents

Medical Mycology

Volumn 49, Issue SUPPL. 1, 2011, Pages

  Van Der Linden, Jan W M ^a   Warris, Adilia ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antifungal agents; Aspergillus species; invasive aspergillosis; resistance; susceptibility testing

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; PYRROLE; VORICONAZOLE;

ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS USTUS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECIES DISTRIBUTION; TREATMENT OUTCOME; VIRUS PNEUMONIA;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

ASPERGILLUS; ASPERGILLUS FUMIGATUS;

EID: 79952654257     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.499916     Document Type: Conference Paper

References (62)

1. Levine SJ. An approach to the diagnosis of pulmonary infections in immunosuppressed patients. Semin Respir Infect 1992; 7: 81-95.
2. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-1458.
3. Verweij PE, Mellado E, Melchers WJG. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356: 1481-1483.
4. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-1076.
5. Snelders E, van der Lee HAL, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PloS Med 2008; 5: e219.
6. Arendrup MC, Garcia-Effron G, Buzina W, et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009; 53: 1185-1193.
7. Snelders E, Huis in't Veld RAG, Rijs AJJM, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical tria-zoles. Appl Envir Microbiol 2009; 75: 4053-4057.
8. Verweij PE, Snelders E, Kema GHJ, Mellado E, Melchers WJG. Azole-resistance in Aspergillus fumigatus : a side effect of environmental fungicide use? Lancet Infect Dis 2009; 9: 789-795.
9. Hong SB, Shin HD, Hong J, et al. New taxa of Neosartorya and Aspergillus in Aspergillus section Fumigati. Antonie Van Leeuwen-hoek 2008; 93: 87-98.
10. Balajee SA, Nickle D, Varga J, Marr KA. Molecular studies reveal frequent misIdentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell 2006; 5: 1705-1712. (Pubitemid 44622598)
11. Balajee SA, Gribskov J, Brandt M, et al. Mistaken identity: Neosar-torya pseudof scheri and its anamorph masquerading as Aspergillus fumigatus. J Clin Microbiol 2005; 43: 5996-5999. (Pubitemid 43100650)
12. Verweij PE, Howard SJ, Melchers WJG, Denning DW, et al. Azole resistance in Aspergillus : proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12: 141-147.
13. Rodriguez-Tudela JL, Alcazar-Fuoli L, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimi-crob Agents Chemother 2008; 52: 2468-2472. (Pubitemid 351915677)
14. Pfaller MA, Diekema DJ, Ghannoum MA, et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee. J Clin Micro-biol 2009; 47: 3142-3146.
15. Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmaco-therapy 2005; 25:1174-1180. (Pubitemid 41242577)
16. Johnson EM, Oakley KL, Radford SA, et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000; 45: 85-93. (Pubitemid 30060238)
17. Balajee SA, Kano R, Baddley JW, et al. Molecular Identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3138-3141.
18. Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3271-3275.
19. Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49: 102-111.
20. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based Identification. Antimicrob Agents Chemother 2008; 52: 1244-1251. (Pubitemid 351521983)
21. Vinh DC, Shea YR, Jones PA, et al. Chronic invasive aspergillosis caused by Aspergillus viridinutans. Emerg Infect Dis 2009; 15: 1292-1294.
22. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 2005; 4: 625-632. (Pubitemid 40383765)
23. Montenegro G, Sánchez Puch S, Jewtuchowicz VM, et al. Phenotypic and genotypic characterization of Aspergillus lentulus and Aspergillus fumigatus isolates in a patient with probable invasive aspergillosis. J Med Microbiol 2009; 58: 391-395.
24. Alhambra A, Catalán M, Moragues MD, et al. Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev Iberoam Micol 2008; 25: 246-249.
25. Sugui JA, Vinh DC, Nardone G, et al. Neosartorya udagawae (Asper-gillus udagawae ), an emerging agent of aspergillosis: how different is it from Aspergillus fumigatus? J Clin Microbiol 2010: 48: 220-228.
26. Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus f avus: an emerging non-fumigatus Aspergillus species of significance. Mycoses 2009; 52: 206-222.
27. Gomez-Lopez A, Garcia-Effron G, Mellado E, et al. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2003; 47: 3085-3088. (Pubitemid 37229561)
28. Hsueh PR, Lau YJ, Chuang YC, et al. Antifungal susceptibilities of clinical isolates of candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan Program Data from 2003. Antimicrob Agents Chemother 2005: 49: 512-517.
29. Lionakis MS, Lewisa RL, Torresa HA, et al. Increased frequency of non- fumigatus Aspergillus species in amphotericin B- or triazole pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005: 52: 15-20. (Pubitemid 40692735)
30. Koss T, Bagheri B, Zeana C, Romagnoli MF, Grossman ME. Amphot-ericin B-resistant Aspergillus f avus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol 2002; 46: 945-947.
31. Bowman JC, Abruzzo GK, Flattery AM, et al. Efficacy of caspofungin against Aspergillus f avus, Aspergillus terreus, and Aspergillus nidu-lans. Antimicrob Agents Chemother 2006; 50: 4202-4205. (Pubitemid 44865171)
32. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidu-lans infection in chronic granulomatous disease. Medicine 1998; 77: 345-354. (Pubitemid 28449835)
33. Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2001; 45: 406-407.
34. Verweij PE, Varga J, Houbraken J, et al. Emericella quadrilineata as cause of invasive aspergillosis. Emerg Infect Dis 2008; 14: 566-572. (Pubitemid 351520857)
35. Varga J, Houbraken J, Van der Lee HAL, Verweij PE, Samson RA. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell 2008; 7: 630-638. (Pubitemid 351959897)
36. Houbraken J, Due M, Varga J, et al. Polyphasic taxonomy of Aspergil-lus section Usti. Stud Mycol 2007; 59: 107-128. (Pubitemid 351155592)
37. Verweij PE, Van Den Bergh MFQ, PM Rath, et al. Invasive asper-gillosis caused by Aspergillus ustus : case report and review. J Clin Microbiol 1999; 37: 1606-1609. (Pubitemid 29187849)
38. Pavie J, Lacroix C, Hermoso DG, et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2003; 43: 4902-4904. (Pubitemid 41298308)
39. Panackal AA, Imhof A, Hanley EW, Marr KA. Aspergillus ustus infections among transplant recipients. Emerg Infect Dis 2006; 12: 403-408.
40. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised def nitions of invasive fungal disease from the European Organization for Research and Treatment of cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
41. Lass-Flörl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL. In vitro activities of various antifungal drugs against Aspergillus terreus : Global assessment using the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2009; 53: 794-795.
42. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergil-lus terreus, with a head to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-2345. (Pubitemid 29277804)
43. Steinbach WJ, Benjamin DK, Jr., Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-198. (Pubitemid 38971489)
44. Castón JJ, Linares MJ, Gallego C, et al. Risk factors for pulmonary Aspergillus terreus infection in patients with positive culture for f lamentous fungi. Chest 2007; 131:230-236. (Pubitemid 46122998)
45. Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus : 10-year single centre experience. Br J Haematol 2005; 131: 201-207. (Pubitemid 43899686)
46. Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594-1600. (Pubitemid 39318906)
47. Graybill JR, Hernandez S, Bocanegra R, Najvar LK. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48: 3715-3719. (Pubitemid 39304594)
48. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188: 305-319. (Pubitemid 36898165)
49. Deak E, Wilson SD, White E, Carr JH, Balajee SA. Aspergillus terreus accessory conidia are unique in surface architecture, cell wall composition and germination kinetics. PLoS One 2009; 4: e7673.
50. Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother 2008; 52: 1553-1555. (Pubitemid 351522034)
51. Samson RA, Noonim P, Meijer M, et al. Diagnostic tools to identify black Aspergilli. Stud Mycol 2007; 59: 129-145. (Pubitemid 351155593)
52. Kaya AD, Kiraz N. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Mycoses 2007; 50: 447-450. (Pubitemid 47609822)
53. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Species Identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother 2009; 53: 4514-4517.
54. Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008: 46: 2568-2572.
55. Balajee SA, Baddley JW, Peterson SW, et al. Aspergillus alabamensis, a new clinically relevant species in the section Terrei. Eukaryot Cell 2009; 8: 713-722.
56. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005: 43: S49-S58. (Pubitemid 41038548)
57. Kredics L, Varga J, KocsubéS, et al. Infectious keratitis caused by Aspergillus tubingensis. Cornea 2009; 28: 951-954.
58. Torres-Rodríguez JM, Madrenys-Brunet N, Siddat M, et al. Asper-gillus versicolor as cause of onychomycosis: report of 12 cases and susceptibility testing to antifungal drugs. J Eur Acad Dermatol Venereol 1998; 11: 25-31. (Pubitemid 28383611)
59. Takahata Y, Hiruma M, Sugita T, et al. A case of onychomycosis due to Aspergillus sydowii diagnosed using DNA sequence analysis. Mycoses 2007; 51: 170-173. (Pubitemid 351191115)
60. Chiu YL, Liaw SJ, Wu VC, et al. Peritonitis caused by Aspergillus sydowii in a patient undergoing continuous ambulatory peritoneal dialysis. J Infect 2005; 51: e156-e161.
61. Zotti M, Machetti M, Perotti M, et al. A new species, Aspergillus persii, as an agent of onychomycosis. Med Mycol 2010; 48: 656-660.
62. Tarrand JJ, Han XY, Kontoyiannis DP, May GS. Aspergillus hyphae in infected tissue: evidence of physiologic adaptation and effect on culture recovery. J Clin Microbiol 2005; 43: 382-386. (Pubitemid 40096327)